Acquisitions Management Operations Branch, NIAID, 6003 Executive Blvd, Solar Building, Room 1A25, Contracts Section, Bethesda MD 20892-7605

A -- CHARACTERIZATION AND SAFETY TESTING OF CLINICAL RETROVIRUS VECTOR PRODUCER LINES, RETROVIRUS VECTOR SUPERNATANTS, AND EX-VIVO GENE ALTERED CELLS FOR GENE THERAPY SOL NIAID-DIR-95-53 DUE 051795 POC Mollie Shea, Contract Specialist, 301-496-3878 Mollie Shea, Contracting Officer, 301-496-3878. The Laboratory of Host Defenses, Division of Intramural Research National Institute of Allergy and Infectious Diseases is seeking an organization having the capabilities for safety testing relating to retrovirus producer cell lines, retrovirus supernatants, and gene altered target cells which will allow the NIAID/DIR/LHD to conduct a clinical gene therapy trial with retrovirus materials that will satisfy and conform to all current U.S. FDA rules and regulations for retrovirus producer cell line growth and frozen storage, retrovirus supernatant production and storage, and safety testing and written documentation. RFP issuance o/a April 17, 1995. See Numbered Note 1. No telephone requests for RFPs will be accepted. See Numbered Note(s): 1. (0093)

Loren Data Corp. http://www.ld.com (SYN# 0006 19950404\A-0006.SOL)